iBio - IBIO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares.
View IBIO analyst ratings or view top-rated stocks.

iBio saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 2,030,000 shares, a decrease of 5.6% from the February 13th total of 2,150,000 shares. Based on an average daily volume of 3,220,000 shares, the short-interest ratio is currently 0.6 days. Currently, 16.9% of the shares of the stock are sold short.
View iBio's Short Interest.

iBio, Inc. (NYSEAMERICAN:IBIO) issued its quarterly earnings results on Tuesday, February, 14th. The biotechnology company reported ($1.08) EPS for the quarter. iBio had a negative trailing twelve-month return on equity of 106.69% and a negative net margin of 2,054.97%.

Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

iBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.24%), Geode Capital Management LLC (0.85%), Dimensional Fund Advisors LP (0.82%), Millennium Management LLC (0.78%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBIO stock can currently be purchased for approximately $2.10.

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $25.98 million and generates $2.38 million in revenue each year.

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.